Healthcare -
Medical - Devices - NASDAQ - US
$ 2.57
1.18 %
$ 88.2 M
Market Cap
-5.47
P/E
1. INTRINSIC VALUE
Balance Sheet
Monogram Orthopaedics, Inc.
| Current Assets | 14.6 M |
| Cash & Short-Term Investments | 13.6 M |
| Receivables | 365 K |
| Other Current Assets | 664 K |
| Non-Current Assets | 1.96 M |
| Long-Term Investments | 0 |
| PP&E | 1.41 M |
| Other Non-Current Assets | 549 K |
| Current Liabilities | 2.82 M |
| Accounts Payable | 2.46 M |
| Short-Term Debt | 128 K |
| Other Current Liabilities | 228 K |
| Non-Current Liabilities | 364 K |
| Long-Term Debt | 364 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Monogram Orthopaedics, Inc.
| Revenue | 365 K |
| Cost Of Revenue | 0 |
| Gross Profit | 365 K |
| Operating Expenses | 17.6 M |
| Operating Income | -17.3 M |
| Other Expenses | -3.52 M |
| Net Income | -13.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Monogram Orthopaedics, Inc.
| Net Income | -13.7 M |
| Depreciation & Amortization | 412 K |
| Capital Expenditures | -64.9 K |
| Stock-Based Compensation | 1.56 M |
| Change in Working Capital | 1.15 M |
| Others | -3.2 M |
| Free Cash Flow | -13.6 M |
Wall Street Analysts Price Targets
Monogram Orthopaedics, Inc.
MGRM has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
MGRM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Monogram Orthopaedics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA
Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Request Management Anticipates a Comprehensive AIR Response in Q1 2025 AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application"). The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.
accesswire.com
- 1 month ago
Monogram Technologies Inc. (MGRM) Q3 2024 Earnings Call Transcript
Monogram Technologies Inc. (NASDAQ:MGRM ) Q3 2024 Earnings Call Transcript November 19, 2024 4:30 PM ET Company Participants Ben Sexson - CEO Noel Knape - CFO Larry Holub - IR Conference Call Participants Tom Kerr - Zacks Investment Research Operator Greetings and welcome to the Monogram Technologies Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 2 months ago
Monogram Technologies Reports Third Quarter 2024 Financial Results
Closed an Upsized and Oversubscribed $13 Million Public Offering to Fund Near-term Commercialization Milestones Management to Host Business Update Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / November 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the third quarter ended September 30, 2024.
accesswire.com
- 2 months ago
Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time
AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones.
accesswire.com
- 2 months ago
Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024
Award from Medical Tech Outlook Highlights Monogram's mBôs TKA System AUSTIN, TX / ACCESSWIRE / October 29, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has been named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook. Monogram Technologies mBôs TKA Precision Robotic Surgical System This award is in recognition of Monogram's stellar reputation and trust among customers and industry peers, evident in the numerous nominations received from Medical Tech Outlook's subscribers.
accesswire.com
- 2 months ago
Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024
AUSTIN, TX / ACCESSWIRE / October 16, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will attend the LD Micro Main Event XVII Conference being held at the Luxe Sunset Blvd Hotel in Los Angeles, CA October 29 - 30, 2024. Monogram Chief Financial Officer Noel Knape will conduct in-person one-on-one meetings during the conference to discuss the Company's novel mBôs precision robotic surgical system.
accesswire.com
- 3 months ago
CORRECTION FROM SOURCE: Monogram Technologies Issues Correction to Press Release Announcing it Received an FDA Response for its mBôs TKA System
Company Has 180 Days From Receipt to Produce Additional Information AUSTIN, TX / ACCESSWIRE / October 3, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced a correction to its press release issued on Wednesday, October 2, 2024, entitled "Monogram Technologies Receives FDA Response for mBôs TKA System" (the "Prior Press Release"). In yesterday's prior press release, dated October 2, 2024, it was stated in the subtitle that: "Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days.
accesswire.com
- 3 months ago
Monogram Technologies Receives FDA Response for mBôs TKA System
Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has received an Additional Information Request ("AIR") from the U.S. Food and Drug Administration ("FDA") on September 30, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application"). The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.
accesswire.com
- 3 months ago
Monogram Technologies Announces Closing of Upsized and Oversubscribed $13 Million Public Offering
AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today that the Company closed the previously announced 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") continuous offering on October 1, 2024. The Company sold 5,790,479 units, with each unit consisting of (a) one share of the Company's Series D Preferred Stock and (b) one common stock purchase warrant to purchase one share of the Company's common stock, $0.001 par value per share (the "Common Stock"), for a total of 5,790,479 shares of the Company's Series D Preferred Stock and warrants to purchase an aggregate of 5,790,479 shares of the Company's Common Stock (and shares of Common Stock underlying shares of Series D Preferred Stock, PIK dividends on Series D Preferred Stock, and all such warrants).
accesswire.com
- 3 months ago
Monogram Technologies Announces Preferred Stock Dividends
AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024.
accesswire.com
- 3 months ago
Monogram Technologies Upsizes 8.00% Series D Convertible Cumulative Preferred Stock and Warrant Offering to $12.5 Million
AUSTIN, TX / ACCESSWIRE / September 11, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced an upsize of its previously announced continuous offering of units from $10 million to $12.5 million of units. Each unit consists of (a) one share of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") and (b) one common stock purchase warrant to purchase one share of its common stock, $0.001 par value per share (the "Common Stock").
accesswire.com
- 4 months ago
Monogram Technologies Reports Second Quarter 2024 Financial Results
Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System Secured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby Limited Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / August 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the second quarter ended June 30, 2024.
accesswire.com
- 5 months ago
8. Profile
Summary
Monogram Orthopaedics, Inc. MGRM
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 88.2 M
Dividend Yield
0.14%
Description
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Contact
3913 Todd Lane, Austin, TX, 78744
https://www.monogramorthopedics.com
IPO
Date
May 18, 2023
Employees
28
Officers
Mr. Benjamin Sexson C.F.A.
Chairman of the Board, President & Chief Executive Officer
Chris Tyson
Executive Vice President - MZ North America
Mr. Noel Knape C.P.A., M.B.A.
Chief Financial Officer
Dr. Kamran Shamaei Ph.D.
Chief Technology Officer
Dr. Douglas Unis
Founder, Chief Medical Officer & Director